9M and Q3 2023 results
AstraZeneca 9 November 2023 9M and Q3 2023 results Strong momentum in the year to date leads to increased guidance for Total Revenue ex COVID-19 medicines and Core EPS Revenue and EPS summary 9M 2023 Q3 2023 % Change % Change $m Actual CER $m Actual CER- Product Sales 32,466 1 4 11,018 4 5 - Alliance Revenue 1,004 99 99 377 76 75 -